Video 09 Apr 2026 Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US… Orthocell
Company News, Video 01 Apr 2026 Investor Presentations | March 2026 Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on… Orthocell
Company News 25 Mar 2026 The Armchair Analyst | What makes a surgeon adopt a product? Surgeon adoption is a key factor in the commercialisation of medical technologies. But what influences whether a surgeon chooses to adopt… Orthocell
Company News 18 Mar 2026 Remplir™ Used in 23 Surgeries on Injured Soldiers in Ukraine Orthocell has announced that its Remplir™ nerve repair device has been used in 23 surgical procedures on injured soldiers in Ukraine. Orthocell
Company News, Video 02 Feb 2026 February 2026 Orthocell Investor Webinar Replay In this webinar, Orthocell Chair, John Van Der Wielen, CEO and MD, Paul Anderson, and Independent Director, Dr Ravi Thadani provide an important operational update… Orthocell
Company News, Media 26 Jan 2026 Orthocell Co-Founder Professor Minghao Zheng Appointed Member of the Order of Australia (AM) Orthocell proudly congratulates our Co-Founder and Chief Scientific Officer, Professor Minghao Zheng AM, on being appointed a Member of the… Orthocell
Company News 19 Jan 2026 Quarterly Report for period ended 31 December 2025 Orthocell has today released its Quarterly Report for the period ended 31 December 2025 – a quarter marked by continued revenue growth and accelerating U.S. commercialisation. Orthocell
Video 19 Jan 2026 AFR | The company repairing human bone with Kimberley pearl shells. The AFR has profiled Orthocell’s increased investment in Marine Biomedical and its novel bone-repair technology, PearlBone™, in this article by… Orthocell
Company News 16 Jan 2026 Ausbiz | Interview with John Van Der Wielen Orthocell Chairman John Van Der Wielen recently spoke with ausbiz about the Company’s strategic investment in Marine Biomedical and the rationale behind securing global distribution rights to PearlBone™. Orthocell
Video 16 Jan 2026 Orthocell Finalises Formal Agreement with Marine Biomedical and Secures Strategic Rights to Groundbreaking Bone Regeneration Technology, PearlBone™ Orthocell has entered into a binding Formal Agreement with @Marine Biomedical, increasing its equity interest from 1.72% to 11.7% for a total… Orthocell
